Signet Therapeutics Wins AIBC Awards 2026 'Innovation Breakthrough Award' and Files IPO Prospectus

This award represents a high recognition of SIGNET’s steadfast adoption of the novel “organoid + AI” R&D paradigm since its establishment in late 2020, which systematically enhances the efficiency and success rate of new drug development by addressing the fundamental nature of diseases. It also serves as an authoritative affirmation of the company’s pioneering role globally in advancing the “organoid + AI” technological pathway to the clinical validation stage and its continuous generation of first-in-class innovative pipelines.

About the AIBC Awards: Discovering True Innovation Power

AI technology has deeply permeated the entire chain from target discovery and molecular optimization to clinical trials, reshaping the efficiency of biopharmaceutical innovation. As a prestigious industry event, AIBC2026 features the AIBC Awards—the Annual List of AI-Driven Pharmaceutical Companies—which conducts rigorous multi-dimensional evaluations based on technical capabilities, R&D achievements, and commercialization progress, aiming to identify benchmark enterprises that possess both technological barriers and industrial value. The list includes the “Industry Leadership Award” and the “Innovation Breakthrough Award,” which outline the landscape of industry innovation from the perspectives of “height” and “sharpness,” respectively, providing a credible barometer for the sector.

SIGNET: Reconstructing the Underlying Logic of Cancer Drug Discovery with “Organoids + AI”

SIGNET’s receipt of the “Innovation Breakthrough Award” stems from our profound insight into and systematic resolution of a fundamental pain point in the field of novel cancer drug development. Traditional drug development adheres to a harsh law:10 Years, $1 Billion, 10% Success Rate. Ninety percent of drug candidates fail during clinical trials, not because of inadequate molecular design, but because the models used for testing differ substantially from the human body—two-dimensional cell cultures cannot recapitulate the three-dimensional tumor microenvironment, and animal experiments fail to reproduce human tumor heterogeneity.

SIGNET’s solution is to reconstruct this chain from the ground up.

The "organoid" model we have developed is a three-dimensional, functionally organ-like miniature structure cultivated in vitro from pluripotent stem cells. It is not merely a model that "resembles an organ," but rather a“Transplanting Real Tumors into Petri Dishes”disease reducer. On this basis, AI transcends the limitations of traditional molecular libraries by virtually designing millions of drug molecules and conducting rapid screening, followed by real-world validation of the screened molecules using organoids. This set of"Organoid Model Building — AI-Driven Molecular Design — Organoid-Based Drug Efficacy Validation"closed loop, transforming drug development from “groping in the dark” to “targeted precision.”

The value of SIGNET’s technological framework has been validated across the entire chain, from industry to regulatory authorities.

In 2021, less than a year after its establishment, SIGNET was featured by globally renowned biotechnology media Fierce Biotech As a front-page report, rated as“NEXT Generation Paradigm for Cancer Drug Development”In April 2025, the U.S. FDA officially issued a statement explicitly supporting the gradual replacement of traditional animal testing with organoid and AI technologies—a policy signal that validates the technological pathway SIGNET has adhered to since its inception.Forward-Looking and Scientific Rigor。

Winning the “Innovation Breakthrough Award” at the AIBC Awards signifies industry recognition of SIGNET’s “organoid + AI” technological approach, and further affirms our mission to “start from the essence of disease and translate cutting-edge science into clinical value.” SIGNET will continue to deepen its efforts in the field of cancer innovative targeted drug development driven by “organoid + AI,” committed to making more source innovations originating from China accessible as treatment options for global patients at an earlier stage.

SIGNET is a pioneer in the innovative “organoid + AI”-enabled targeted drug development model, recognized as a National High-Tech Enterprise and a Specialized, Refined, Differential, and Innovative (SRDI) Enterprise. Its founding team comprises outstanding talents from top-tier institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. The team has published over 20 groundbreaking research papers in high-impact journals (impact factor >20), including Nature, Nature Medicine, and Cancer Cell, as first or corresponding authors, focusing on tumors such as gastric and esophageal cancers, thereby establishing itself as a global leader in gastric and esophageal cancer research. Since establishing its operations in Shenzhen in late 2020, the company has secured nearly RMB 300 million in financing and project grants, and holds more than 40 core intellectual property rights.

The company has currently established a portfolio comprising multiple first-in-class drug pipelines and an organoid service platform. Its core pipeline, SIGX1094, as the world’s first targeted therapy for diffuse gastric cancer, has sequentially received Investigational New Drug (IND) approval from both the U.S. FDA and China’s NMPA, and has been granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the U.S. FDA. In August 2025, this drug was nominated for the Galien Prize, often referred to as the “Nobel Prize of the pharmaceutical industry.” It is currently undergoing Phase I clinical trials at Peking University Cancer Hospital and is poised to initiate Phase II clinical trials. Notably, this pipeline represents the first globally to advance to the clinical stage via an “organoid + AI” technology platform. The second drug pipeline, SIGX2649, is a pan-TEAD inhibitor targeting key downstream effectors of the Hippo signaling pathway. As there are currently no marketed drugs for this target, it has already obtained IND approval from the U.S. FDA. The organoid service platform not only supports the company’s internal drug pipelines but also actively empowers major pharmaceutical companies in their new drug R&D efforts. Collaborative partners include Shenzhen Second People’s Hospital, The University of Hong Kong, The Hong Kong University of Science and Technology, Shenzhen BrightGene Bio-Medical Technology, and Jiangsu Zhenau Biotechnology, among others, contributing to the development of more innovative therapies.

Since its inception in late 2020, the company’s forward-looking strategic layout of the “organoid + AI”-enabled technology platform for innovative targeted cancer drug development has gained international authoritative recognition. It was featured on the homepage of Fierce Biotech, a globally renowned biotechnology media outlet, and hailed as the “NEXT Generation paradigm for cancer drug development.” In April 2025, the U.S. FDA officially issued a statement explicitly supporting the gradual replacement of traditional animal testing with organoid and AI technologies, fully validating the foresight and scientific rigor of the company’s technological strategy established four years prior.